Zacks Research Expects Weaker Earnings for Acadia Healthcare

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) – Analysts at Zacks Research dropped their Q2 2026 earnings estimates for shares of Acadia Healthcare in a report issued on Wednesday, March 11th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.49 for the quarter, down from their previous forecast of $0.66. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Acadia Healthcare’s current full-year earnings is $3.38 per share. Zacks Research also issued estimates for Acadia Healthcare’s FY2026 earnings at $1.48 EPS and FY2027 earnings at $1.55 EPS.

Acadia Healthcare (NASDAQ:ACHC) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. The firm had revenue of $821.46 million for the quarter, compared to the consensus estimate of $800.10 million. Acadia Healthcare had a positive return on equity of 6.53% and a negative net margin of 33.29%.The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.64 earnings per share. Acadia Healthcare has set its FY 2026 guidance at 1.300-1.550 EPS and its Q1 2026 guidance at 0.250-0.300 EPS.

A number of other equities analysts have also weighed in on the stock. KeyCorp decreased their price target on shares of Acadia Healthcare from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, December 3rd. Mizuho reduced their price target on shares of Acadia Healthcare from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Acadia Healthcare in a research note on Wednesday, January 21st. Raymond James Financial restated an “outperform” rating and set a $25.00 price target on shares of Acadia Healthcare in a research report on Thursday, February 26th. Finally, Barclays raised their price objective on Acadia Healthcare from $14.00 to $20.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 3rd. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $21.15.

Acadia Healthcare Trading Up 1.1%

NASDAQ:ACHC opened at $24.15 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.55 and a current ratio of 1.55. The firm has a market cap of $2.23 billion, a P/E ratio of -1.98, a P/E/G ratio of 8.07 and a beta of 0.74. The firm’s fifty day moving average is $16.61 and its 200-day moving average is $18.77. Acadia Healthcare has a 52 week low of $11.43 and a 52 week high of $31.04.

Hedge Funds Weigh In On Acadia Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Allworth Financial LP boosted its stake in Acadia Healthcare by 676.4% in the second quarter. Allworth Financial LP now owns 1,351 shares of the company’s stock worth $31,000 after buying an additional 1,177 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Acadia Healthcare by 54.8% during the second quarter. EverSource Wealth Advisors LLC now owns 1,404 shares of the company’s stock valued at $32,000 after purchasing an additional 497 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Acadia Healthcare by 208.9% during the 4th quarter. Wells Fargo & Company MN now owns 2,233 shares of the company’s stock worth $32,000 after purchasing an additional 1,510 shares during the period. Bayforest Capital Ltd purchased a new position in Acadia Healthcare in the 4th quarter worth approximately $52,000. Finally, Hantz Financial Services Inc. raised its stake in Acadia Healthcare by 501.9% during the third quarter. Hantz Financial Services Inc. now owns 2,185 shares of the company’s stock worth $54,000 after acquiring an additional 1,822 shares in the last quarter.

More Acadia Healthcare News

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Acadia named Daniel Cancelmi to its board, a routine corporate-governance move that can be seen as a small positive for investor confidence around management and oversight. Acadia Healthcare Appoints Daniel Cancelmi to Board of Directors
• Neutral Sentiment: Short-interest reports in the recent filings appear unreliable or contain errors (showing 0 shares and NaN changes); there’s no clear evidence from these data of rising short pressure driving the move. Monitor for corrected filings if short-seller activity is a concern.
• Negative Sentiment: Analyst cuts from Zacks Research: the firm sharply trimmed EPS estimates across multiple quarters and fiscal years (Q1–Q4 2026 estimates and multiple 2027 quarters, plus FY2026/FY2027 reductions). Zacks now forecasts FY2026 EPS ~ $1.48 and FY2027 EPS ~ $1.55 (well below the street consensus cited at $3.38), and cut near-term quarterly forecasts (e.g., Q2 2026 to $0.49). Those widespread downgrades and a maintained “Hold” rating put clear downside pressure by lowering near-term earnings expectations and increasing uncertainty about earnings recovery.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.